COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,235 Articles (22,733 medRxiv, 8,502 bioRxiv)

Most recent first Previous |  Page 696: Articles 6951-6960  | Next

SARS-CoV-2 oral tablet vaccination induces neutralizing mucosal IgA in a phase 1 open label trial
Johnson, S., Martinez, C. I., Jegede, C. B., Gutierrez, S., Cortese, M., Martinez, C. J., Garg, S. J., Peinovich, N., Dora, E. G., Tucker, S. N.
10.1101/2022.07.16.22277601 — Posted: 2022-07-19
Experimental infection of Mexican free-tailed bats (Tadarida brasiliensis) with SARS-CoV-2.
Hall, J., Hofmeister, E., Ip, H., Nashold, S., Leon, A., Malave, C., Falendysz, E., Rocke, T., Carossino, M., Balasuriya, U., Knowles, S.
10.1101/2022.07.18.500430 — Posted: 2022-07-18
Efficacy of the AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine Against SARS-CoV-2 Variants of Concern
Koen, A. L., Izu, A., Baillie, V., Kwatra, G., Cutland, C. L., Fairlie, L., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., Briner, C., Ahmed, K., Bhikha, S., Bhiman, J. N., du Plessis, J., Esmail, A., Horne, E., Hwa, S.-H., Oomen-Jose, A., Lambe, T., Laubscher, M., Malahleha, M., Benade, G., McKenzie, S., Oelofse, S., Patel, F., Pillay, S., Rhead, S., Rodel, H., Taoushanis, C., Tegally, H., Thombrayil, A., Villafana, T., Gilbert, S., Pollard, A. J., Madhi, S.
10.1101/2022.07.18.22277743 — Posted: 2022-07-18
Clinical utility of repurposing a short course of hepatitis C drugs for COVID19. A randomized controlled study
Yakoot, M., Eysa, B., Gouda, E., Helmy, S. A., Elsayed, M. R., Elrouby, O., Mohamed, A., Reyad, E., Fawzi, M. M., Elmandouh, S., Abdellatif,, W., Zidan, A. A., Adel, A.-E., Hassany, M.
10.1101/2022.07.18.22277477 — Posted: 2022-07-18
Identification of a Papain-Like Protease Inhibitor with Potential for Repurposing in Combination with an Mpro Protease Inhibitor for Treatment of SARS-CoV-2
Campagna, J., Jagodzinska, B., Alvarez, P., Yeun, C., Spilman, P., Enquist, K. M., Cohn, W., Fajtov, P., O'Donoghue, A. J., Arumugaswami, V., Li, M. M. H., Damoiseaux, R., John, V.
10.1101/2022.07.18.500363 — Posted: 2022-07-18
Model training periods impact estimation of COVID-19 incidence from wastewater viral loads
Daza-Torres, M. L., Montesinos-Lopez, J. C., Kim, M., Olson, R., Bess, C. W., Rueda, L., Susa, M., Tucker, L., Garcia, Y. E., Schmidt, A. J., Naughton, C., Pollock, B. H., Shapiro, K., Nuno, M., Bischel, H. N.
10.1101/2022.07.16.22276772 — Posted: 2022-07-18
Exploring Impacts to COVID-19 Herd Immunity Thresholds Under Demographic Heterogeneity that Lowers Vaccine Effectiveness
Paris, C. F., Spencer, J. A., Castro, L. A., Del Valle, S. Y.
10.1101/2022.07.18.22277763 — Posted: 2022-07-18
COVID-19 vaccine effectiveness against progression to in-hospital mortality -- Zambia, 2021-2022
Chanda, D., Hines, J. Z., Itoh, M., Fwoloshi, S., Minchella, P. A., Zyambo, K. D., Sivile, S., Kampamba, D., Chirwa, B., Chanda, R., Mutengo, K., Kayembe, M. F., Chewe, W., Chipimo, P., Mweemba, A., Agolory, S., Mulenga, L. B.
10.1101/2022.07.18.22277749 — Posted: 2022-07-18
A simple SEIR-V model to estimate COVID-19 prevalence and predict SARS-CoV-2 transmission using wastewater-based surveillance data
Phan, T., Brozak, S., Pell, B., Gitter, A., Mena, K. D., Kuang, Y., Wu, F.
10.1101/2022.07.17.22277721 — Posted: 2022-07-18
Ad26.COV2.S priming provides a solid immunological base for mRNA-based COVID-19 booster vaccination
Geers, D., Sablerolles, R., van Baarle, D., Kootstra, N., Rietdijk, W., Schmitz, K., Bogers, S., Gommers, L., Nieuwkoop, N., van Dijk, L., van Haren, E., Lafeber, M., Dalm, V. A. S. H., Goorhuis, B., Postma, D., Visser, L., Huckriede, A., Sette, A., Grifoni, A., de Swart, R., Koopmans, M., van der Kuy, H., GeurtsvanKessel, C., de Vries, R. D.
10.1101/2022.07.15.22277639 — Posted: 2022-07-18

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).